Bicyclic Aryl S1P Receptor Agonists for Selective Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for novel, potent, and selective agonists or antagonists of the S1P receptor with enhanced potency, selectivity, and oral bioavailability to target specific cellular responses without causing unwanted side effects, particularly for conditions like multiple sclerosis, autoimmune diseases, and inflammatory disorders.
Innovation Solution
Development of compounds with specific structural formulas that can act as S1P receptor agonists or antagonists, including those with formula (I), which are designed to selectively target S1P1, S1P4, or S1P5 receptors, thereby modulating sphingosine-1-phosphate receptor activity to induce desired cellular responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If S1P receptor agonists are developed to target specific cellular responses, then therapeutic benefits are improved, but unwanted side effects occur due to lack of selectivity
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural modifications at particular positions of the S1P receptor ligand structure. The bicyclic aryl group at the R1 position and specific substituent patterns create localized interactions with distinct S1P receptor subtypes, enabling selective activation of desired cellular responses while avoiding activation of receptors that would cause side effects
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters such as the bicyclic aryl structure, substituent types (halo, alkyl, alkoxy, nitro, cyano groups), and positional isomers to fine-tune receptor selectivity. These parameter modifications alter the binding affinity and specificity for different S1P receptor subtypes, achieving therapeutic efficacy with minimized side effects
2Reliability
If S1P receptor agonists are designed for high potency, then treatment efficacy is enhanced, but selectivity among different S1P receptor subtypes decreases
Solution Approach 1:
The patent achieves both potency and selectivity through local quality modifications where specific functional groups and their positions on the bicyclic aryl structure create localized binding characteristics. The R1 bicyclic aryl group with specific substituents provides strong binding (potency) while the unique spatial arrangement ensures selective interaction with target S1P receptor subtypes
Solution Approach 2:
The patent utilizes asymmetry in the molecular structure, particularly in the bicyclic aryl group configuration and substituent positioning, to achieve selective binding. The asymmetric arrangement of functional groups allows the compound to fit specifically into certain S1P receptor binding pockets while excluding others, thereby maintaining both high potency and subtype selectivity
3Object-generated harmful factors
If S1P receptor antagonists are developed to block specific receptors, then side effects are minimized, but oral bioavailability decreases
Solution Approach 1:
The patent addresses oral bioavailability through parameter changes in the molecular structure, including the bicyclic aryl group, substituent types, and overall molecular weight and lipophilicity parameters. These modifications optimize the compound's pharmacokinetic properties to enable adequate oral absorption while maintaining selective antagonist activity that minimizes side effects
Data Source
AI summary
Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphin-gosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.